Smith Hayes Advisers’s Teva Pharmaceuticals TEVA Stock Holding History

Smith Hayes Advisers’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$654K	Sell	12,217 -699	-5%	-$41K	0.13%	176
2015 Q4	$848K	Sell	12,916 -199	-2%	-$12.3K	0.18%	146
2015 Q3	$738K	Sell	13,115 -549	-4%	-$35.6K	0.16%	154
2015 Q2	$808K	Sell	13,664 -1,323	-9%	-$81.6K	0.16%	146
2015 Q1	$934K	Buy	14,987 +3	+0%	+$174	0.19%	137
2014 Q4	$862K	Sell	14,984 -57	-0.4%	-$3.18K	0.18%	146
2014 Q3	$808K	Buy	15,041 +3	+0%	+$159	0.19%	136
2014 Q2	$788K	Buy	15,038 +4	+0%	+$204	0.18%	145
2014 Q1	$794K	Buy	15,034 +204	+1%	+$9.43K	0.2%	141
2013 Q4	$594K	Buy	14,830 +1,559	+12%	+$61.4K	0.2%	137
2013 Q3	$501K	Buy	13,271 +224	+2%	+$8.74K	0.19%	134
2013 Q2	$511K	Buy	+13,047	New	+$508K	0.21%	119

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Smith Hayes Advisers's TEVA Position: Q1 2016 in Review

Smith Hayes Advisers reduced its Teva Pharmaceuticals (TEVA) stake by 5.4% in Q1 2016, selling an estimated $41K and leaving 12,217 shares worth $654K. The position accounts for 0.13% of the portfolio, ranked #176.

Smith Hayes Advisers first reported a position in TEVA in Q2 2013 and has held it in 12 quarters since. The position peaked at $934K in Q1 2015. 836 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

Smith Hayes Advisers held 12,217 shares of Teva Pharmaceuticals worth $654K as of Q1 2016.
Smith Hayes Advisers sold 699 Teva Pharmaceuticals shares in Q1 2016, an estimated $41K.
Teva Pharmaceuticals made up 0.13% of Smith Hayes Advisers's portfolio in Q1 2016, its #176 holding.
Smith Hayes Advisers first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 12 quarters since.
Smith Hayes Advisers's Teva Pharmaceuticals position peaked at $934K in Q1 2015.
836 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on Smith Hayes Advisers's 13F filing for Q1 2016, filed 16 May 2016.